Hemorrhoid Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global hemorrhoid treatment market size is expected to be valued at US$ 1.2 billion in 2026 and projected to reach US$ 2.0 billion by 2033, growing at a CAGR of 7.4% between 2026 and 2033.

The increasing prevalence of hemorrhoidal disease is driven by sedentary lifestyles, aging populations, obesity, chronic constipation, and poor dietary habits. Rising awareness of early diagnosis and the availability of effective treatment options are encouraging more patients to seek medical care.

The market includes medications, minimally invasive procedures, and surgical interventions, with growing preference for outpatient treatments that offer faster recovery and reduced complications. Technological advancements in laser therapy, stapling devices, and office-based procedures, along with expanding healthcare access, favorable reimbursement policies, and increasing over-the-counter product availability, continue to support sustained market expansion worldwide.

Drivers - Rising Prevalence of Hemorrhoidal Disease Linked to Lifestyle Factors

Hemorrhoidal disease prevalence continues climbing steadily across both developed and developing regions. The American Society of Colon and Rectal Surgeons reports that a substantial share of adults will experience hemorrhoidal symptoms at some point during their lifetime. Sedentary work patterns, low dietary fiber intake, and chronic constipation continue to contribute to rising hemorrhoid incidence rates across urban populations worldwide. This growing patient base is prompting primary care physicians to refer more patients toward specialized colorectal and gastroenterology practices for evaluation and treatment.

The National Institute of Diabetes and Digestive and Kidney Diseases continues tracking gastrointestinal disorder prevalence linked to modern dietary patterns. As awareness of hemorrhoid symptoms and treatment options continues spreading through public health education, patients are seeking care earlier, expanding the addressable treatment population across all severity grades. Growing dietary fiber supplementation marketing also reinforces public awareness of underlying risk factors.

Expanding Adoption of Office-Based Minimally Invasive Procedures

Office-based minimally invasive procedures continue reshaping hemorrhoid treatment pathways across outpatient settings. Rubber band ligation, sclerotherapy, and infrared coagulation procedures allow physicians to treat symptomatic hemorrhoids without requiring operating room facilities or general anesthesia.

The American Society of Colon and Rectal Surgeons continues recommending these office-based procedures as first-line intervention for grade one through three internal hemorrhoids that fail conservative medication management. This procedural shift reduces patient recovery time and overall treatment cost compared with traditional surgical hemorrhoidectomy. Companies such as Medtronic plc and CooperSurgical, Inc. continue expanding device portfolios supporting these office-based procedural techniques.

As gastroenterology and colorectal surgery practices continue investing in procedural equipment for in-office treatment, patient access to minimally invasive intervention keeps expanding across both hospital-affiliated and independent specialty clinic settings. Growing patient preference for same-day recovery further reinforces demand for these office-based procedural approaches.

Market Restraints

Patient Reluctance to Seek Timely Medical Evaluation

Many patients delay seeking medical evaluation for hemorrhoidal symptoms due to embarrassment or the assumption that symptoms will resolve without intervention. This delayed presentation often allows hemorrhoidal disease to progress to more severe grades requiring more invasive treatment approaches.

The American Society of Colon and Rectal Surgeons has noted that patient hesitancy around discussing anorectal symptoms remains a persistent barrier to early diagnosis. Primary care physicians report that patients frequently self-treat with over-the-counter remedies for extended periods before seeking specialist evaluation. This delayed care-seeking behavior can result in less favorable treatment outcomes and higher overall treatment costs. Patients in rural areas with limited specialist access face even greater delays before receiving appropriate evaluation.

Symptom Recurrence Following Non-Surgical Treatment Approaches

Hemorrhoidal symptoms frequently recur following non-surgical treatment approaches such as topical medications and minimally invasive office procedures. Clinical literature published through gastroenterology and colorectal surgery journals continues documenting recurrence rates following rubber band ligation and sclerotherapy procedures within several years of initial treatment. This recurrence pattern can discourage patients from pursuing conservative treatment options in favor of more definitive surgical intervention.

Recurring symptoms also increase the overall cost burden on healthcare systems as patients require repeated treatment cycles. This treatment durability challenge remains a persistent limitation across non-surgical hemorrhoid management approaches broadly. Patients with recurring symptoms often require additional diagnostic evaluation, further compounding overall treatment costs.

Opportunities - Growing Demand for Advanced Minimally Invasive Procedural Devices

Advanced minimally invasive procedural devices present a substantial growth opportunity for medical device manufacturers serving the hemorrhoid treatment market. Techniques such as transanal hemorrhoidal dearterialization and stapled hemorrhoidopexy continue gaining clinical adoption as alternatives to traditional excisional surgery.

Companies such as Medtronic plc and ConMed Corporation continue expanding specialized surgical stapling and energy-based device portfolios supporting these advanced procedural techniques. Growing colorectal surgeon training in these newer procedural approaches continues expanding the pool of physicians capable of offering advanced minimally invasive treatment options. Device manufacturers that invest in physician training programs alongside procedural device development can build stronger long-term relationships with colorectal surgery practices. As ambulatory surgical centers continue expanding capacity for same-day anorectal procedures, manufacturers supplying compatible devices stand to capture growing procedural volume across both hospital and outpatient surgical settings.

Expansion of Home Care and Over-the-Counter Treatment Options

Home care and over-the-counter treatment options present a growth opportunity as patients increasingly seek convenient, accessible first-line symptom management. Pharmacies and drugstores continue expanding shelf space dedicated to topical hemorrhoid treatment products, including creams, suppositories, and medicated wipes. Companies such as Pfizer Inc. and Bayer AG maintain established over-the-counter hemorrhoid treatment brands with strong consumer recognition across major retail channels.

Growing telehealth consultation availability allows patients to receive treatment guidance and prescription topical medications without requiring in-person specialist visits for milder symptom presentations. Manufacturers that expand accessible, easy-to-use home care formulations can capture growing consumer demand for convenient self-management options. This opportunity is particularly strong among younger patients seeking discreet, at-home treatment before considering in-office or surgical intervention pathways.

Treatment Type Analysis

Medication held the leading position among treatment types, accounting for approximately 45% share of the market in 2025. This leadership reflects medication's role as the standard first-line treatment approach recommended for mild to moderate hemorrhoidal symptoms before considering procedural intervention. Physicians and patients alike prefer starting with topical or oral medication given its lower cost, convenience, and absence of procedural recovery time.

The American Society of Colon and Rectal Surgeons continues recommending conservative medical management as the initial treatment approach for grade one and grade two internal hemorrhoids. Companies such as Pfizer Inc. and Sanofi maintain extensive over-the-counter and prescription hemorrhoid medication portfolios. While Minimally Invasive Procedures are growing faster as patients seek definitive symptom resolution, medication's role as the universal first-line treatment keeps this category dominant through the forecast period. Continued reformulation toward faster-acting topical agents further reinforces this category's broad appeal.

Drug Type Analysis

Topical Medications held the leading position among drug types, capturing an estimated 52% share of the market in 2025. This leadership reflects topical formulations' direct application convenience and rapid symptom relief for itching, pain, and inflammation associated with hemorrhoidal disease. Creams, ointments, and suppositories remain widely available without prescription requirements across most major markets, supporting broad consumer accessibility.

Companies such as Bayer AG and 3M Company maintain established topical hemorrhoid treatment product lines distributed across pharmacy and grocery retail channels. Injectable Treatments are growing faster as sclerotherapy procedure adoption increases within office-based settings, but topical medications' accessibility and established consumer trust keep this drug type category dominant through the forecast period. Continued retail shelf expansion for topical hemorrhoid products further reinforces this segment's strong consumer visibility.

End User Analysis

Hospitals represented the leading end user category, holding an estimated 34% share of the market in 2025. This dominance reflects hospitals' capability to manage the full spectrum of hemorrhoid treatment, from conservative medication management through complex surgical hemorrhoidectomy for severe cases. Hospitals also maintain the anesthesia and post-operative care infrastructure required for patients with significant comorbidities or complicated hemorrhoidal disease presentations.

Companies such as Johnson & Johnson and B. Braun SE supply surgical instruments and consumables supporting hospital-based hemorrhoid procedures. Ambulatory Surgical Centers (ASCs) are growing quickly as minimally invasive procedure volume shifts toward outpatient settings, but hospitals' capability to manage complex and high-risk cases keeps this end user category dominant through the forecast period. Growing referral pathways from primary care physicians further reinforce hospital-based specialist consultation volume.

North America Hemorrhoid Treatment Market Trends and Insights

North America led the hemorrhoid treatment market, holding an estimated 37% share in 2026. Strong healthcare infrastructure and high patient awareness of minimally invasive treatment options drive this leadership. Growing adoption of office-based procedural techniques continues strengthening regional demand across the United States and Canada. Expanding ambulatory surgical center capacity further reinforces this regional leadership position.

U.S. Hemorrhoid Treatment Market Size

The United States accounts for the majority of North American demand. Strong colorectal surgery infrastructure and high patient awareness support this leading position. Growing demand for office-based minimally invasive procedures continues expanding demand. The U.S. market is expected to maintain steady growth through the forecast period.

Europe Hemorrhoid Treatment Market Trends and Insights

Europe represents a mature and steadily growing hemorrhoid treatment market. Strong gastroenterology and colorectal surgery training infrastructure continues strengthening regional demand. Growing consumer interest in minimally invasive treatment options continues shaping product innovation. Europe is expected to remain a significant contributor to global market growth.

Germany Hemorrhoid Treatment Market Size

Germany holds a leading position within the European market. Strong healthcare infrastructure and research collaboration support this leadership. Companies such as B. Braun SE maintain robust production capacity within the country. Growing demand for advanced minimally invasive treatment devices continues strengthening demand. Germany should remain Europe's largest market through the forecast period.

U.K. Hemorrhoid Treatment Market Size

The United Kingdom holds a significant share of the European market. Strong National Health Service colorectal referral pathways support growing procedure volumes. Rising demand for office-based treatment options continues strengthening market activity nationwide. Growing patient awareness of minimally invasive alternatives supports demand. The United Kingdom's market should keep growing steadily through the forecast period.

France Hemorrhoid Treatment Market Size

France contributes a meaningful share to the European market. Strong gastroenterology specialist training capacity supports steady hemorrhoid treatment demand nationwide. Growing consumer interest in minimally invasive procedures continues strengthening demand within outpatient settings. Rising over-the-counter medication availability supports continued treatment volume. France should continue growing steadily alongside broader European market trends.

Asia Pacific Hemorrhoid Treatment Market Trends and Insights

Asia Pacific is projected to register the fastest growth in the coming years. Rising healthcare investment and growing awareness of treatment options drive this growth. China is emerging as a key regional contributor, with growing domestic demand for both medication and procedural hemorrhoid treatment. Rising healthcare infrastructure investment across the region continues strengthening demand. Expanding specialist training programs across major regional hospitals further support this growth trajectory.

India Hemorrhoid Treatment Market Size

India shows growing demand for hemorrhoid treatment. Rising healthcare infrastructure and growing specialist training capacity support this growth. Companies continue expanding distribution networks to serve growing urban patient demand. Growing awareness of treatment options is expanding referral volumes. India's market should continue growing steadily through the forecast period.

The hemorrhoid treatment market remains moderately fragmented, comprising large multinational medical device and pharmaceutical companies alongside specialized surgical device makers. Companies such as Johnson & Johnson and Medtronic plc compete through broad surgical device portfolios and established hospital relationships. Pharmaceutical companies including Pfizer Inc. and Sanofi differentiate through established over-the-counter and prescription medication brands.

Market leaders are investing in physician training programs and expanding minimally invasive device platforms. Strategic partnerships between device manufacturers and ambulatory surgical centers continue strengthening outpatient procedure adoption. Growing emphasis on office-based procedural technology reflects an industry-wide shift toward convenience-focused, outpatient treatment delivery. Expanding investment in patient education campaigns further differentiates leading manufacturers from smaller competitors.

Key Developments:

• In May 2026, Quest Products, Inc. expanded the retail availability of Doctor Butler's Maximum Strength Relief Formula by launching the proctologist-developed hemorrhoid and fissure ointment in Walmart stores nationwide.
• In March 2025, Quest Products, LLC, backed by Promus Equity Partners, acquired Beyond Health, P.A., owner of the Doctor Butler's® hemorrhoid care brand. The acquisition expands Quest's digestive health portfolio and strengthens its position in the over-the-counter (OTC) hemorrhoid treatment market.